SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-159884
Filing Date
2023-06-02
Accepted
2023-06-02 16:31:04
Documents
12
Period of Report
2023-05-26
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d487918d8k.htm   iXBRL 8-K 22215
  Complete submission text file 0001193125-23-159884.txt   142953

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA onct-20230526.xsd EX-101.SCH 2856
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE onct-20230526_lab.xml EX-101.LAB 17994
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE onct-20230526_pre.xml EX-101.PRE 11265
6 EXTRACTED XBRL INSTANCE DOCUMENT d487918d8k_htm.xml XML 3357
Mailing Address 12230 EL CAMINO REAL SUITE 230 SAN DIEGO CA 92130
Business Address 12230 EL CAMINO REAL SUITE 230 SAN DIEGO CA 92130 (858) 434-1113
Oncternal Therapeutics, Inc. (Filer) CIK: 0001260990 (see all company filings)

IRS No.: 621715807 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-50549 | Film No.: 23989356
SIC: 2834 Pharmaceutical Preparations